Opportunistic screening for cirrhosis and steatotic liver disease — from the subcostal view captured during routine echocardiography.
Chronic liver disease affects more than 1.5 billion adults worldwide, and most cases are asymptomatic and undiagnosed. Early cirrhosis can present with symptoms — fatigue, weakness, poor appetite, leg and abdominal swelling — that mimic heart failure, so patients may be worked up for the wrong condition entirely.
During every standard echocardiographic exam, the subcostal view captures the liver alongside the heart. Cardiologists typically aren't trained to evaluate hepatic texture and quality, so this information goes unused. InVision Precision Cirrhosis applies deep learning to the subcostal echo view to opportunistically screen for cirrhosis and steatotic liver disease — no additional imaging, no additional patient time.
The underlying EchoNet-Liver pipeline was developed from over 1.5 million echocardiogram videos and validated against paired abdominal ultrasound and MRI studies at two large academic medical centers. The research was peer-reviewed in NEJM AI (2025). In November 2025, the FDA granted Breakthrough Device Designation to Precision Cirrhosis, providing an expedited pathway for regulatory review. A prospective multi-center validation trial is underway, funded by the American Heart Association.